We developed a RIA involving a polyclonal antibody against bovine osteocalcin, which has a carboxy-terminal epitope. Although the antibody recognizes both native and descarboxy osteocalcin, the two forms of osteocalcin were differentiated by adsorption to barium sulfate, taking advantage of the calcium-binding properties of the vitamin K-dependent gla domain. To test the clinical application of undercarboxylated osteocalcin, we examined the effect of minidose warfann on this measure in nine healthy subjects, ages 60 to 80 years.The percentage of undercarboxylated osteocalcin increased by 170% ± 36% (mean ± SE) after 7 days of treatment with warfatin, 1 mg/day. The effectiveness of undercarboxylated osteocalcin as a sensitive measure of vitamin K nutritional status was further established when concentrations dropped to 17% ± 14% below baseline with 2 days of repletion with vitamin K1, 5 mg/day, during which prothrombin times did not leave the normal range.
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Osteocalcin is a 49-residue, 5700-Da protein found in bone and dentin (1) . Osteocalcin requires vitamin K for its synthesis, with the vitamin functioning as a cofactor for a microsomal carboxylase in the posttranslational synthesis of three specific glutamic acid residues to 'y-carboxyglutamic acid (gla) (2) . These gla residues allow the protein to bind to calcium and therefore also to hydroxyapatite.
If sufficient vitamin K is not available because of a dietary deficiency or vitamin K antagonism by anticoagulants, the osteocalcin produced lacks some or all of the gla residues.
The carboxylation state of osteocalcin, determined by the differential binding of osteocalcin and its undercarboxylated form to hydroxyapatite, has been shown to be responsive to changes in vitamin K status (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . In addition, an increase in undercarboxylated osteocalcin has been shown to be indicative of risk of hip fracture in elderly institutionalized women (13) , which adds to the grow- 
Materials and Methods
Purification of Osteocalcin
Minidose Warfann Subjects
The nine healthy ambulatory subjects (four men, five women) who pai"ticipated in this study were recruited from the Boston area and ranged in age from 60 to 80 years [69 ± 6 (mean ± SD) years]. Percent of original concentration 
Results
Osteocalcirt Assay Characterization
Analytical recoveries of added osteocalcin were compared in normal serum and in serum from subjects who were treated for 7 days with 1 mg/day of warfarin. Recoveries from the normal and warfarinized speci- .c
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osteocalcin molecule that includes amino acids 31 to 36. However, when a peptide of this region was synthesized and tested in the RIA, no cross-reactivity was observed (Fig. 3) (mean ± SE) between osteocalcin measured in serum and osteocalcin measured in EDTA, sodium citrate, and sodium heparin plasma. Only sodium hepann plasma specimens were significantly different from serum (P = 0.001).Specimenswere obtained from 16 healthy tastingsubjects (7 men, 9 women), ages25 to 72. trations in sodium heparin plasma specimens were significantly higher than those in serum (P = 0.001), with an average difference of 7.8% ± 1.8% (SE). The effects observed were similar for both men and women.
Changes in Undercarboxylated Osteocalcin with Minidose Warfann Administration
The response of undercarboxylated osteocalcin to antagonism with minidose warfarin therapy was examined in nine healthy subjects, ages 60 to 80 years. As shown in Fig. 6 , there was a significant increase of 170% ± 36% (P <0.01) in undercarboxylated osteocaldin, as compared with baseline (day 5), after 7 days of minidose warfarin administration (1 mg/day); i.e., values increased from 15% ± 4% to 38% ± 9%. After 2 days of repletion with 5 mg of vitamin K1, values dropped rapidly to 10% ± 2%, concentrations that were an average of 17% ± 14% below baseline (P <0.05). These changes can be attributed to the undercarboxylated portion of osteocalcin, there being no changes in total osteocalcin during the study period (Fig. 6 ). Throughout the study the prothrombin time did not leave the normal range, and there was no effect of warfarin or vitamin K1 dosing as compared with baseline in these same subjects, although the values after the depletion and repletion phases (days 12 and 14) were significantly different (P = 0.005).
Discussion
Since the discovery that osteocalcin can be quantified in serum and (or) plasma ( (4) (5) (6) (7) (8) (9) . Only two of these studies defined the doses of anticoagulants given, which in general were >1 mg/day, and, as they did not specify in the others, it was assumed that the patients were not uniformly on low-dose regimens as in this study. In addition to changes in undercarboxylated osteocalcin, the total amount of osteocalcin decreased in some (4, 6, 7), but not all (4, 7, 8) , studies.
Previously, warfarm was shown to affect the secretion of osteocalcin from the osteoblast in an in vitro study (57). Gender and age differences between the treatment and control groups may explain some of the similar concentrations (4, 8, 9) . In this study total osteocalcin #{232}oncentrations did not change, possibly reflecting the decreased dose or short time of administration. 
